Study design (if review, criteria of inclusion for studies)
prospective, randomized, double-blind, parallel-group, controlled study
Participants
patients with cystic fibrosis and lung disease
Interventions
a hypertonic saline solution containing hyaluronic acid (Hyaneb) versus standard hypertonic saline
Outcome measures
tolerability of hypertonic saline
Main results
The results showed that nebulized Hyaneb was more effective in reducing the need for beta(2) bronchodilators and caused a significant reduction in the incidence of adverse effects compared with nebulized hypertonic saline solution alone. Its safety profile indicates that Hyaneb can be used for the treatment of lung disease in cystic fibrosis.